Nektar Therapeutics Upsizes Public Offering to $325 Million
Event summary
- Nektar Therapeutics priced an upsized public offering of 3,532,609 shares at $92.00 per share.
- The offering raised gross proceeds of approximately $325 million, exceeding initial expectations.
- Nektar has granted underwriters a 30-day option to purchase an additional 529,891 shares.
- Proceeds will be used for general corporate purposes, including Phase 3 clinical trials for rezpegaldesleukin.
- The offering is expected to close on April 23, 2026.
The big picture
Nektar's upsized offering underscores the continued investor appetite for immunotherapy plays, particularly those with differentiated regulatory T cell modulation approaches. The substantial capital infusion provides a runway for critical Phase 3 trials, but also increases the pressure to deliver positive clinical data and demonstrate a clear path to commercialization. The offering's size suggests a belief in the potential of rezpegaldesleukin, but also highlights the capital intensity of late-stage drug development.
What we're watching
- Clinical Execution
- The success of rezpegaldesleukin's Phase 3 trials will be critical to justifying the capital raised and driving future valuation, given the substantial investment being made.
- Shareholder Dilution
- The increased share count will dilute existing shareholders, and the stock's performance will depend on Nektar's ability to deliver on its clinical milestones and create shareholder value.
- Capital Allocation
- How effectively Nektar deploys the raised capital across its pipeline, beyond rezpegaldesleukin, will determine its long-term growth trajectory and potential for further financing needs.
Related topics